Alnylam Pharmaceuticals (ALNY) reported $594.19 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 20.2%. EPS of -$0.01 for the same period compares to -$0.16 a year ago.

The reported revenue represents a surprise of +1.02% over the Zacks Consensus Estimate of $588.18 million. With the consensus EPS estimate being -$0.56, the EPS surprise was +98.21%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Product revenues, net: $468.54 million compared to the $464.60 million average estimate based on 10 analysts. The reported number represents a change of +28.3% year over year.
• Revenues- Net revenues from research collaborators: $99.19 million versus the nine-analyst average estimate of $93.37 million. The reported number represents a year-over-year change of -16.3%.
• Revenues- Royalty revenue: $26.47 million versus the nine-analyst average estimate of $30.71 million. The reported number represents a year-over-year change of +149.2%.
• Net Product Revenues- Givlaari: $66.97 million versus the six-analyst average estimate of $67.46 million. The reported number represents a year-over-year change of +15.4%.
• Net Product Revenues- Oxlumo: $42.09 million compared to the $44.67 million average estimate based on six analysts. The reported number represents a change of -1.3% year over year.
• Net Product Revenues- Amvuttra: $309.99 million versus the five-analyst average estimate of $300.02 million. The reported number represents a year-over-year change of +58.8%.
• Net Product Revenues- Onpattro: $49.49 million versus $51.23 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -28.5% change.
• Net revenues from research collaborators- Other: $31.09 million compared to the $3 million average estimate based on two analysts.
• Net revenues from research collaborators- Regeneron Pharmaceuticals: $51.04 million compared to the $22.50 million average estimate based on two analysts.

View all Key Company Metrics for Alnylam here>>>

Shares of Alnylam have returned -1.4% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research